Work

Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)

Year: 2000

Type: article

Source: Lung Cancer

DOI: 10.1016/s0169-5002(00)80233-0

Authors: M.G Kris, R Herbst, D Rischin, P LoRusso, J Baselga, L Hammond, A Feyereislova, J Ochs, S Averbuch

Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Peter MacCallum Cancer Centre, Harper University Hospital, AstraZeneca (United Kingdom), AstraZeneca (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1985153867

FWCI: 12.01

Cites:

Cited by: 63

Related to: 10